Vincent Picozzi
Overview
Explore the profile of Vincent Picozzi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
588
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chiorean E, Picozzi V, Li C, Peeters M, Maurel J, Singh J, et al.
Cancer Med
. 2023 Oct;
12(20):20353-20364.
PMID: 37840530
Background: Pancreatic ductal adenocarcinomas (PDAC) are characterized by frequent cell cycle pathways aberrations. This study evaluated safety and efficacy of abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, as monotherapy...
2.
Rosenzweig A, Berlin J, Chari S, Kindler H, Matrisian L, Mayoral A, et al.
Oncologist
. 2023 Apr;
28(7):584-595.
PMID: 37043728
Pancreatic cancer is one of the few cancer types in the US with incidence and death rates continuing to rise. As the disease threatens to become the second leading cause...
3.
Garcia J, Dunne R, Santiago K, Martin L, Birnbaum M, Crawford J, et al.
J Cachexia Sarcopenia Muscle
. 2022 Feb;
13(2):1418-1425.
PMID: 35218313
No abstract available.
4.
Picozzi V, Alseidi A, Winter J, Pishvaian M, Mody K, Glaspy J, et al.
ESMO Open
. 2020 Aug;
5(4).
PMID: 32817130
Purpose: Pancreatic ductal adenocarcinomas exhibit a high degree of desmoplasia due to extensive extracellular matrix deposition. Encasement of mesenteric vessels by stroma in locally advanced pancreatic cancer (LAPC) prevents surgical...
5.
Sahai V, Saif M, Kalyan A, Philip P, Rocha-Lima C, Ocean A, et al.
J Pancreat Cancer
. 2019 Sep;
5(1):35-42.
PMID: 31559379
To evaluate safety and preliminary efficacy of metronomic 5-fluorouracil plus -paclitaxel, bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with newly diagnosed metastatic pancreatic cancer (MPC). A total of 12 treatment-naive...
6.
Hu Z, Bendell J, Bullock A, Loconte N, Hatoum H, Ritch P, et al.
Cancer Med
. 2019 Jul;
8(11):5148-5157.
PMID: 31347292
Purpose: Notch signaling dysregulation is implicated in the development of pancreatic adenocarcinoma (PDAC). Tarextumab is a fully human IgG2 antibody that inhibits Notch2/3 receptors. Patients And Methods: Aphase 2, randomized,...
7.
Pishvaian M, Bender R, Matrisian L, Rahib L, Hendifar A, Hoos W, et al.
Oncotarget
. 2017 Nov;
8(48):83446-83456.
PMID: 29137355
Recent improvements in next-generation sequencing (NGS) technology have enabled detection of biomarkers in cell-free DNA in blood and may ultimately replace invasive tissue biopsies. However, a better understanding of the...
8.
Picozzi V, Narayanan S, Hu X, Vacirca J
J Gastrointest Cancer
. 2016 Dec;
48(1):103-109.
PMID: 28028766
Purpose: Due to its clinical course and often-late detection, many patients with metastatic pancreatic cancer (mPC) experience poor quality of life (QoL). This pilot project assessed real-world QoL in patients...
9.
Oh S, Edwards A, Mandelson M, Ross A, Irani S, Larsen M, et al.
Gastrointest Endosc
. 2015 Apr;
82(3):460-8.e2.
PMID: 25851162
Background: Data on endoscopic stenting of malignant gastric outlet obstruction (GOO) are based on studies predominantly involving patients with pancreatic adenocarcinoma. Objective: To compare survival and clinical outcome after stent...
10.
Le D, Wang-Gillam A, Picozzi V, Greten T, Crocenzi T, Springett G, et al.
J Clin Oncol
. 2015 Jan;
33(12):1325-33.
PMID: 25584002
Purpose: GVAX pancreas, granulocyte-macrophage colony-stimulating factor-secreting allogeneic pancreatic tumor cells, induces T-cell immunity to cancer antigens, including mesothelin. GVAX is administered with low-dose cyclophosphamide (Cy) to inhibit regulatory T cells....